308 CHAPTER 4.1 Table SI1.1. Continued. STOPP criteria (n=79) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) H 6. Long-term NSAID or colchicine (>3 months) for chronic treatment of gout where there is no contraindication to a xanthine-oxidase inhibitor (e.g. allopurinol, febuxostat) 9 11.1% 1 0% 2 0% 2 0% 4 25.0% K 4. Hypnotic Z-drugs e.g. zopiclone, zolpidem, zaleplon (in patients with risk of falls) 9 88.9% 0 N/A 4 75.0% 3 100% 2 100% D 1. Tricyclic Antidepressants (TCAs) with dementia, narrow angle glaucoma, cardiac conduction abnormalities, prostatism, or prior history of urinary retention 8 87.5% 0 N/A 4 100% 1 100% 3 66.7% E 4. NSAID’s if eGFR < 50 ml/min/1.73m2 8 75.0% 1 0.0% 7 85.7% 0 N/A 0 N/A H 3. Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain where paracetamol has not been tried 8 37.5% 1 100% 3 33.3% 4 25.0% 0 N/A H 7. COX-2 selective NSAIDs with concurrent cardiovascular disease 8 100% 0 N/A 2 100% 0 N/A 6 100% I 2. Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic hypotension or micturition syncope 8 50.0% 0 N/A 3 0.0% 1 100% 4 75.0%
RkJQdWJsaXNoZXIy MTk4NDMw